Oncology Trials In The Time Of COVID-19: Expert Insights

Best practices for managing ongoing cell and gene therapy trials

Personalized medicine is radically changing how the world looks at cancer therapy. Having completed more than 170 hematology and oncology trials, we know what it takes to optimize studies for these next-generation biotherapies with expertise ranging from small dose-finding studies to large multinational trials.

In this virtual presentation, we explore how cell and gene therapies are being used to treat tumors, discuss design and operational considerations for new early-phase trials, and review the pandemic’s impact on the clinical trial environment.